EUVIMEDEUVIMED entdecken
Open Access

HLA class I-specific nucleolin peptides induce therapeutic T cells in triple-negative breast cancer patients

Suyanee Thongchot, Niphat Jirapongwattana, Thaweesak Chieochansin, Jaturawitt Prasopsiri, Wannasiri Chiraphapphaiboon, Piriya Luangwattananun, Thanyada Rungrotmongkol, Kamonpan Sanachai, Nitchakan Darai, Doonyapat Sa-Nguanraksa, Pornchai O-Charoenrat, Peti Thuwajit und 2 weitere

International Journal of Biological Sciences · 20.07.2026 · 22 (12) · 6814-6835

DOI: 10.7150/ijbs.132389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biological Sciences, erschienen am 20.07.2026. Verfasst von Suyanee Thongchot und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, RNA-Binding Proteins, Phosphoproteins, Peptides. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsRNA-Binding ProteinsPhosphoproteinsPeptidesHistocompatibility Antigens Class IHumansNucleolinFemaleCell Line, TumorAntibodies, Monoclonal, HumanizedCD8-Positive T-LymphocytesMDA-MB-231 Cells

Stichwörter der Autor:innen

HLA class Iimmunotherapynucleolinshort peptidetriple-negative breast cancer

Substanzen

RNA-Binding ProteinsNucleolinPhosphoproteinsPeptidesHistocompatibility Antigens Class IAntibodies, Monoclonal, Humanizedatezolizumab

Autor:innen und Institutionen

  • Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
  • Siriraj Center of Research Excellence for Cancer Immunotherapy, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
  • Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand.
  • Hematología computacional y genómica (GrHeCo-Xen), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela 15706 Spain.
  • Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330 Thailand.
  • Program in Bioinformatics and Computational Biology, College of Interdisciplinary and Integrative Studies, Chulalongkorn University, Bangkok 10330 Thailand.

Zitieren

APA

Thongchot, S., Jirapongwattana, N., Chieochansin, T., Prasopsiri, J., Chiraphapphaiboon, W., Luangwattananun, P., Rungrotmongkol, T., Sanachai, K., Darai, N., Sa-Nguanraksa, D., O-Charoenrat, P., Thuwajit, P., Yenchitsomanus, P. T., & Thuwajit, C. (2026). HLA class I-specific nucleolin peptides induce therapeutic T cells in triple-negative breast cancer patients. International Journal of Biological Sciences, 22(12), 6814-6835. https://doi.org/10.7150/ijbs.132389

Vancouver

Thongchot S, Jirapongwattana N, Chieochansin T, Prasopsiri J, Chiraphapphaiboon W, Luangwattananun P, et al. HLA class I-specific nucleolin peptides induce therapeutic T cells in triple-negative breast cancer patients. International Journal of Biological Sciences. 2026;22(12):6814-6835. doi:10.7150/ijbs.132389

BibTeX
@article{Thongchot2026,
  author = {Thongchot, Suyanee and Jirapongwattana, Niphat and Chieochansin, Thaweesak and Prasopsiri, Jaturawitt and Chiraphapphaiboon, Wannasiri and Luangwattananun, Piriya and Rungrotmongkol, Thanyada and Sanachai, Kamonpan and Darai, Nitchakan and Sa-Nguanraksa, Doonyapat and O-Charoenrat, Pornchai and Thuwajit, Peti and Yenchitsomanus, Pa-Thai and Thuwajit, Chanitra},
  title = {HLA class I-specific nucleolin peptides induce therapeutic T cells in triple-negative breast cancer patients},
  journal = {International Journal of Biological Sciences},
  year = {2026},
  volume = {22},
  number = {12},
  pages = {6814--6835},
  doi = {10.7150/ijbs.132389}
}
Kostenlos starten →